FDA Greenlights Easier Path for Scar-Reducing Light Therapy Devices
Published Date: 5/1/2026
Rule
Summary
The FDA is officially classifying phototherapy devices that help reduce the look of fresh surgical cuts as Class II, meaning they have special safety rules but are easier to get to patients. This change, effective May 1, 2026, makes it safer and simpler for companies to offer these devices without the toughest regulations. Patients and makers both win with better access and less red tape!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Device moved to Class II, easier market access
The FDA officially classified phototherapy devices for reducing the appearance of acute post-surgical incisions as Class II (special controls), effective May 1, 2026, with the classification applicable December 3, 2021. This puts the device in a lower regulatory class than automatic Class III and lets sponsors rely on the De Novo/510(k) pathway and enables the device to serve as a predicate for future 510(k) devices.
Manufacturers must meet special testing and labeling
To fall within Class II, manufacturers must meet special controls including non-clinical performance testing (spectrum and power verification, heat dissipation, biophotonic properties), biocompatibility and sterility testing, shelf-life demonstration for the photoconverter gel, electromagnetic/electrical/thermal safety testing, software verification/validation and hazard analysis, and specific labeling (technical specs, eye-safety warnings, and gel shelf life). These requirements are codified at 21 CFR 878.4880.
Patients may see improved access to device
FDA states that classifying these phototherapy devices into Class II will enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens. The final order is effective May 1, 2026, and the device type was classified December 3, 2021.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2026-08494 — Small Business Lending Under the Equal Credit Opportunity Act (Regulation B)
Starting June 30, 2026, new rules will help banks and lenders better track loans to small, women-owned, and minority-owned businesses. These changes make it easier for lenders to follow the rules, improve the quality of loan data, and support fair lending. Lenders must fully comply by January 1, 2028, so small businesses get a fair shot at credit.
Next: 2026-08515 — Overweight and Oversize Items Fee Application
Starting July 12, 2026, the Postal Service will charge a $200 fee for overweight or oversize items found in the mail system or reported in shipping manifests. This fee applies to both retail and commercial mailers, except for items caught and returned during retail transactions. Mailers must pay the fee before their item is released, so watch your package size and weight!